Literature DB >> 12926849

Necrotizing skin lesions and NABs development in a multiple sclerosis patient treated with IFNbeta 1b.

Federica Casoni1, Elisa Merelli, Roberta Bedin, Alessandro Martella, Anna Cesinaro, Antonio Bertolotto.   

Abstract

A case of a severe necrotizing vasculopathic skin lesions occurred in a 43 year old women affected by multiple sclerosis (MS) submitted to IFNbeta-1b has been described. After two months of therapy the patient presented, in injection sites of the abdomen, arms and legs, numerous ulcers. A biopsy of the lesions was performed and evidenced confluent necrosis of the superficial and deep skin tissue with mild infiltration by inflammatory cells and thrombosis in deep blood vessels. The IFNbeta-1b was immediately discontinued and therapy with corticosteroids was started. After 12 months from the onset of the adverse reaction, the skin vasculopathic lesions cicatrised leaving sclerotic areas on the abdomen. Neutralizing antibodies against IFNbeta-1b (NABs) were strongly positive at the onset of the skin ulcers and slowly decreased until the recovery. A possible role of NABs in the development of the skin lesions has been considered.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12926849     DOI: 10.1191/1352458503ms933sr

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  4 in total

Review 1.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

2.  Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis.

Authors:  Annette Kolb-Mäurer; Matthias Goebeler; Mathias Mäurer
Journal:  Int J Mol Sci       Date:  2015-07-02       Impact factor: 5.923

3.  Multiple cutaneous necrotic lesions associated with Interferon beta-1b injection for multiple sclerosis treatment: A case report and literature review.

Authors:  Gita Faghihi; Akram Basiri; Mohsen Pourazizi; Bahareh Abtahi-Naeini; Ali Saffaei
Journal:  J Res Pharm Pract       Date:  2015 Apr-Jun

4.  An update on Peginterferon beta-1a Management in Multiple Sclerosis: results from an interdisciplinary Board of German and Austrian Neurologists and dermatologists.

Authors:  Annette Kolb-Mäurer; Cord Sunderkötter; Borries Kukowski; Sven G Meuth
Journal:  BMC Neurol       Date:  2019-06-15       Impact factor: 2.474

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.